CIBC Bancorp USA’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$72.8M Sell
510,112
-13,961
-3% -$2.12M 0.09% 196
2026
Q2
$82.1M Sell
524,073
-13,740
-3% -$2.06M 0.1% 187
2026
Q1
$82.2M Buy
+537,813
New +$82.4M 0.11% 171

Other funds holding NVS

CIBC Bancorp USA's NVS Position: Q3 2026 in Review

CIBC Bancorp USA reduced its Novartis (NVS) stake by 2.7% in Q3 2026, selling an estimated $2.12M and leaving 510,112 shares worth $72.8M. The position accounts for 0.09% of the portfolio, ranked #196.

CIBC Bancorp USA first reported a position in NVS in Q1 2026 and has held it in 3 quarters since. The position peaked at $82.2M in Q1 2026. 1,560 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • CIBC Bancorp USA held 510,112 shares of Novartis worth $72.8M as of Q3 2026.
  • CIBC Bancorp USA sold 13,961 Novartis shares in Q3 2026, an estimated $2.12M.
  • Novartis made up 0.09% of CIBC Bancorp USA's portfolio in Q3 2026, its #196 holding.
  • CIBC Bancorp USA first reported a position in Novartis in Q1 2026 and has held it in 3 quarters since.
  • CIBC Bancorp USA's Novartis position peaked at $82.2M in Q1 2026.
  • 1,560 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.